Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is a malignant type of cancer arising from the nasopharynx epithelium, which is different from head and neck cancers because of its distinct geographical distribution, high correlation with the Epstein-Barr virus (EBV), and unique pathological types[1]. Radiotherapy is a radical therapy for patients with NPC, with more than 70% of patients having locally advanced disease at first diagnosis; cisplatin concurrent chemotherapy combined with radiotherapy is the cornerstone for locally advanced NPC[2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research